Clinical Trials · NCT07223593
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,205
- Start date
- Oct 2025
- Locations
- 170 sites, 18 countries
- Primary endpoint
- Percent Change from Baseline in Maximum Walking Distance